{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:51:43Z","timestamp":1761897103990},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jdiacomp.2019.107473","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T12:05:12Z","timestamp":1571745912000},"page":"107473","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["When should fixed ratio basal insulin\/glucagon-like peptide-1 receptor agonists combination products be considered?"],"prefix":"10.1016","volume":"33","author":[{"given":"Julia","family":"David","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2019.107473_bb0005","series-title":"Treatment and Education of Diabetes and Related Disorders","article-title":"The efficacy of IDegLira (insulin Degludec\/Liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III Randomized Clinical Trial. Diabetes therapy: research","author":"Linjawi","year":"2016"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/dom.12498","article-title":"One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial","volume":"17","author":"Gough","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1932296815610124","article-title":"IDegLira improves both fasting and postprandial glucose control as demonstrated using continuous glucose monitoring and a standardized meal test","volume":"10","author":"Holst","year":"2015","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0020","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc16-0917","article-title":"Benefits of LixiLan, a titratable fixed-ratio combination of insulin Glargine plus Lixisenatide, versus insulin Glargine and Lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O Randomized Trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0025","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2337\/dc16-0046","article-title":"Efficacy and safety of LixiLan, a titratable fixed-ratio combination of Lixisenatide and insulin Glargine, versus insulin Glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0030","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"Standards of medical care in diabetes-2018","volume":"41","author":"Pharmacologic Approaches to Glycemic Treatment","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0035","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0040","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0045","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0055","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0060","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc11-1928","article-title":"Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets","volume":"35","author":"DeVries","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.107473_bb0065","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/dom.12025","article-title":"Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature","volume":"15","author":"Balena","year":"2013","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872719311353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872719311353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T18:29:25Z","timestamp":1574965765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872719311353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1056872719311353"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.107473","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When should fixed ratio basal insulin\/glucagon-like peptide-1 receptor agonists combination products be considered?","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.107473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107473"}}